Cargando…
Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
The prognosis for metastatic castration‐resistant prostate cancer is unfavorable, and although Poly(ADP)‐ribose polymerase‐1 (PARP‐1) inhibitors have shown efficacy in the treatment of androgen‐receptor dependent malignancies, the limited number of options present obstacles for patients that are not...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186898/ https://www.ncbi.nlm.nih.gov/pubmed/32342655 http://dx.doi.org/10.1002/prp2.586 |